Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 1
2008 1
2009 2
2011 2
2012 1
2013 1
2014 2
2015 1
2017 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, Zakaria C, Szlachtycz D, Yee K, Borden KLB. Assouline S, et al. Among authors: cocolakis e. Haematologica. 2023 Nov 1;108(11):2946-2958. doi: 10.3324/haematol.2023.282791. Haematologica. 2023. PMID: 36951168 Free PMC article. Clinical Trial.
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL. Zahreddine HA, et al. Among authors: cocolakis e. Nature. 2014 Jul 3;511(7507):90-3. doi: 10.1038/nature13283. Epub 2014 May 28. Nature. 2014. PMID: 24870236 Free PMC article.
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient.
Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, Hébert J, Morgan RA, Paquet E, Callahan KP, Jordan CT, Assouline S, Miller WH Jr, Mann KK. Nielsen TH, et al. Among authors: cocolakis e. Front Pharmacol. 2013 Feb 12;4:9. doi: 10.3389/fphar.2013.00009. eCollection 2013. Front Pharmacol. 2013. PMID: 23408639 Free PMC article.
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr. Jamal R, et al. Among authors: cocolakis e. J Immunother Cancer. 2017 Nov 21;5(1):83. doi: 10.1186/s40425-017-0290-x. J Immunother Cancer. 2017. PMID: 29157311 Free PMC article. Clinical Trial.
A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL. Assouline S, et al. Among authors: cocolakis e. Haematologica. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245. Epub 2014 Nov 25. Haematologica. 2015. PMID: 25425688 Free PMC article. Clinical Trial. No abstract available.
15 results